Eptifibatide-induced Acute Profound Thrombocytopenia: a Case Report

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2014 Feb 26

PMID 24564943

Citations 6

Authors

Christos Graidis

Christos Golias

Dimokritos Dimitriadis

Georgios Dimitriadis

Theodosis Bitsis

Ilias Dimitrelos

Afroditi Tsiakou

Konstantinos Charalabopoulos

Affiliations

Soon will be listed here.

Abstract

Background: The interactions among cells or among cells and components of the extracellular matrix, is a crucial pathophysiological process involving some molecules collectively known as adhesion molecules (CAMs). Glycoprotein IIb / IIIa receptors are only restricted to blood platelets and they bind fibrinogen and adhesion proteins such as fibronectin, vitronectin, von Willebrand factor to form cross bridges between adjacent platelets. IIb/IIIa receptor antagonists are an object of intense research activity for target therapy worldwide during the last decades. Three GPIIb/IIIa inhibitors, abciximab, tirofiban, and eptifibatide, have been approved for clinical use. Profound thrombocytopenia is an uncommon but clinically important complication of glycoprotein IIb/IIIa inhibitors.

Case Presentation: This case report discusses a forty-four-year-old male patient with acute coronary syndrome who underwent percutaneous coronary intervention and developed profound thrombocytopenia within 4 hours of first administration of eptifibatide.

Conclusion: This report adds another case of eptifibatide-induced thrombocytopenia to the medical literature and endorses the importance of platelet count monitoring after initiating therapy with this agent.

Citing Articles

A woman with eptifibatide (integrilin)-induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review.

Safi M, Nazari R, Senobari N, Taheri H, Ebrahimi P Clin Case Rep. 2024; 12(4):e8694.

PMID: 38550730 PMC: 10974696. DOI: 10.1002/ccr3.8694.

Eptifibatide-induced acute profound thrombocytopenia: A case report.

Alamin M, Al-Mashdali A, Al Kindi D, Elshaikh E, Othman F Medicine (Baltimore). 2022; 101(42):e28243.

PMID: 36281191 PMC: 9592370. DOI: 10.1097/MD.0000000000028243.

Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.

Byrd G, Custovic S, Byrd D, Miano D, Bathla J, Attallah A Case Rep Crit Care. 2021; 2021:8817067.

PMID: 34327026 PMC: 8302401. DOI: 10.1155/2021/8817067.

Eptifibatide-induced profound thrombocytopaenia: a rare complication.

Mahajan P, Ayub F, Azimi R, Adoni N BMJ Case Rep. 2021; 14(6).

PMID: 34127501 PMC: 8204166. DOI: 10.1136/bcr-2021-241594.

A Case of Hyperacute Severe Thrombocytopenia Occurring Less than 24 Hours after Intravenous Tirofiban Infusion.

Meghrajani V, Sabharwal N, Namana V, Elsheshtawy M, Topi B Case Rep Hematol. 2018; 2018:4357981.

PMID: 29977628 PMC: 5994276. DOI: 10.1155/2018/4357981.

References

Aster R . Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest. 2005; 127(2 Suppl):53S-59S. DOI: 10.1378/chest.127.2_suppl.53S. View

Selleng K, Warkentin T, Greinacher A . Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med. 2007; 35(4):1165-76. DOI: 10.1097/01.CCM.0000259538.02375.A5. View

Jennings L, Haga J, Slack S . Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost. 2001; 84(6):1095-102. View

Bougie D, Wilker P, Wuitschick E, Curtis B, Malik M, Levine S . Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002; 100(6):2071-6. View

George J, Aster R . Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program. 2009; :153-8. PMC: 4413903. DOI: 10.1182/asheducation-2009.1.153. View

Golias C, Tsoutsi E, Matziridis A, Makridis P, Batistatou A, Charalabopoulos K . Review. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. In Vivo. 2007; 21(5):757-69. View

Rauova L, Zhai L, Kowalska M, Arepally G, Cines D, Poncz M . Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2005; 107(6):2346-53. PMC: 1895727. DOI: 10.1182/blood-2005-08-3122. View

Georgolios A, Batistatou A, Charalabopoulos K . Integrins in head and neck squamous cell carcinoma (HNSCC): a review of the current literature. Cell Commun Adhes. 2005; 12(1-2):1-8. DOI: 10.1080/15419060500383093. View

. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2001; 356(9247):2037-44. DOI: 10.1016/S0140-6736(00)03400-0. View

10.

Dager W, Dougherty J, Nguyen P, Militello M, Smythe M . Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007; 27(4):564-87. DOI: 10.1592/phco.27.4.564. View

11.

Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi G, Stankovic G . Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293(17):2126-30. DOI: 10.1001/jama.293.17.2126. View

12.

. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998; 339(7):436-43. DOI: 10.1056/NEJM199808133390704. View

13.

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

14.

. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of.... Circulation. 1997; 96(5):1445-53. DOI: 10.1161/01.cir.96.5.1445. View

15.

Nagge J, Jackevicius C, Dzavik V, Ross J, Seidelin P . Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy. 2003; 23(3):374-9. DOI: 10.1592/phco.23.3.374.32107. View

16.

. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997; 349(9063):1422-8. View

17.

Khaykin Y, Paradiso-Hardy F, Madan M . Acute thrombocytopenia associated with eptifibatide therapy. Can J Cardiol. 2003; 19(7):797-801. View

18.

Bishara A, Hagmeyer K . Acute profound thrombocytopenia following abciximab therapy. Ann Pharmacother. 2000; 34(7-8):924-30. DOI: 10.1345/aph.19299. View

19.

. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994; 330(14):956-61. DOI: 10.1056/NEJM199404073301402. View

20.

Madan M, Berkowitz S . Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J. 1999; 138(4 Pt 2):317-26. DOI: 10.1053/hj.1999.v138.a100465. View